Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.
Blood AdvOct 2, 2026
Mark J Levis, Mehdi Hamadani, Brent R Logan et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase 3 MORPHO trial evaluated the efficacy of gilteritinib versus placebo in post-hematopoietic cell transplantation (HCT) for FLT3-ITD AML patients. The study found significant survival benefits in North American participants, while those in Europe and Asia showed no benefit. Pre-HCT measurable residual disease (MRD) levels were influenced by time to HCT and prior FLT3 inhibitor use.
Key findings
- Participants undergoing transplantation <120 days from AML diagnosis had improved survival with gilteritinib.
- Pre-HCT MRD levels were significantly higher in patients treated with FLT3 inhibitors before HCT (P = .001).
- Geographic differences in practice patterns likely accounted for regional variations in gilteritinib's efficacy.
Why it matters
Understanding the impact of regional practice differences on treatment outcomes can guide clinicians in optimizing post-HCT strategies for FLT3-ITD AML patients, potentially improving survival rates.